GlassScriptPhysician profile
Jeanette K Wendt
NPI 1104811397
$9,423.97
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $9,424.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $8,721.34 | 2019 | |
| Novartis Pharmaceuticals Corporation | $187.06 | 2019 | |
| Acorda Therapeutics, INC | $115.19 | 2019 | |
| Sunovion Pharmaceuticals INC. | $55.46 | 2019 | |
| Genzyme Corporation | $50.29 | 2019 | |
| Ucb, INC. | $49.40 | 2019 | |
| Biogen, INC. | $34.79 | 2019 | |
| Amgen INC. | $29.77 | 2019 | |
| Lundbeck LLC | $24.17 | 2019 | |
| Acadia Pharmaceuticals INC | $24.13 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.58 | 2019 | |
| Medtronic USA, INC. | $18.58 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.39 | 2019 | |
| Mallinckrodt Enterprises LLC | $16.94 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.49 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $14.90 | 2019 | |
| Eisai INC. | $13.61 | 2019 | |
| Zyla Life Sciences, INC. | $10.88 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Research and ownership
$4,616.53 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeanette Wendt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.